1. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients
- Author
-
Marta Bodro, David Cucchiari, Sabina Herrera, Natalia Egri, Eduard Palou, María José Ramírez-Bajo, José Ríos, Manel Juan, Antoni Trilla, Mariona Pascal, Marta Garcia-Pascual, Fritz Diekmann, Jordi Rovira, Elisenda Banon-Maneus, Asunción Moreno, Pedro Ventura-Aguiar, Beatriu Bayés, Jimena Del Risco-Zevallos, Joaquim Casals-Urquiza, Frederic Cofan, Anna Pérez-Olmos, and Anna Vilella
- Subjects
COVID-19 Vaccines ,Globulin ,Infection and infectious agents-viral ,030230 surgery ,Antibodies, Viral ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,medicine ,Humans ,Immunology and Allergy ,Pharmacology (medical) ,RNA, Messenger ,Seroconversion ,Transplantation ,Kidney ,Infectious disease ,Kidney transplantation/nephrology ,biology ,SARS-CoV-2 ,business.industry ,ELISPOT ,COVID-19 ,Original Articles ,medicine.disease ,Kidney Transplantation ,Vaccination ,medicine.anatomical_structure ,Infectious disease (medical specialty) ,Immunology ,biology.protein ,Clinical research/practice ,Original Article ,Antibody ,business ,Vaccine - Abstract
According to preliminary data, seroconversion after mRNA SARS‐CoV‐2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a certain grade of protection against SARS‐CoV‐2. To answer this question, we prospectively studied 148 recipients of either kidney (133) or kidney‐pancreas (15) grafts with assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapside (N) and the S protein at baseline and two weeks after receiving the second dose of the mRNA‐1273 (Moderna) vaccine. At baseline, 31 patients (20.9%) had either IgM/IgG or ELISpot positivity and were considered to be SARS‐CoV‐2‐pre‐immunized, while 117 (79.1%) patients had no signs of either cellular or humoral response and were considered SARS‐CoV‐2‐naïve. After vaccination, naïve patients who developed either humoral or cellular response were finally 65.0%, of which 29.9% developed either IgG or IgM and 35.0% S‐ELISpot positivity. Factors associated with vaccine unresponsiveness were diabetes and treatment with anti‐thymocytes globulins during the last year. Side effects were consistent with that of the pivotal trial and no DSAs developed after vaccination. In conclusion, mRNA‐1273 SARS‐CoV‐2 vaccine elicits either cellular or humoral response in almost two thirds of KTRs.
- Published
- 2021